Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ai-Ming Yu

Showing results (121-130 of 139) with videos related to

Pageof 14
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 3, 2015
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve ChemosensitivityMei-Mei Li, Balasubrahmanyam Addepalli, Mei-Juan Tu, et al.
Biomaterials|May 5, 2019
Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasisJieni Xu, Jingjing Sun, Pui Yan Ho, et al.
Cancer Letters|November 4, 2018
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse modelsMei-Juan Tu, Pui Yan Ho, Qian-Yu Zhang, et al.
Placenta|March 16, 2017
Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signalingLissa N Francois, Ludwik Gorczyca, Jianyao Du, et al.
Journal of Lipid Research|November 3, 2005
Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alphaYusuke Inoue, Ai-Ming Yu, Sun Hee Yim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2026
Metabolomics-based predictive biomarker discovery for thiopurine response in Crohn disease: Plasma histidine as a promising biomarkerSum-Yuet Chan, Kang Chao, Ting Yang, et al.
Theranostics|March 23, 2021
<i>In vivo</i> fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapyPeng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, et al.
Cancer Research Communications|October 23, 2024
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer CellsZachary A Schaaf, Shu Ning, Amy R Leslie, et al.
Frontiers in Oncology|March 13, 2020
The Optimal Outcome of Suppressing Ewing Sarcoma Growth <i>in vivo</i> With Biocompatible Bioengineered miR-34a-5p ProdrugDai-Feng Li, Ying Yuan, Mei-Juan Tu, et al.
Molecular Cancer Therapeutics|August 5, 2022
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide TreatmentShu Ning, Chengfei Liu, Wei Lou, et al.
Pageof 14

Showing results (121-130 of 139) with videos related to

Sort By:
Pageof 14
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 3, 2015
Chimeric MicroRNA-1291 Biosynthesized Efficiently in Escherichia coli Is Effective to Reduce Target Gene Expression in Human Carcinoma Cells and Improve ChemosensitivityMei-Mei Li, Balasubrahmanyam Addepalli, Mei-Juan Tu, et al.
Biomaterials|May 5, 2019
Creatine based polymer for codelivery of bioengineered MicroRNA and chemodrugs against breast cancer lung metastasisJieni Xu, Jingjing Sun, Pui Yan Ho, et al.
Cancer Letters|November 4, 2018
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse modelsMei-Juan Tu, Pui Yan Ho, Qian-Yu Zhang, et al.
Placenta|March 16, 2017
Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signalingLissa N Francois, Ludwik Gorczyca, Jianyao Du, et al.
Journal of Lipid Research|November 3, 2005
Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alphaYusuke Inoue, Ai-Ming Yu, Sun Hee Yim, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 25, 2026
Metabolomics-based predictive biomarker discovery for thiopurine response in Crohn disease: Plasma histidine as a promising biomarkerSum-Yuet Chan, Kang Chao, Ting Yang, et al.
Theranostics|March 23, 2021
<i>In vivo</i> fermentation production of humanized noncoding RNAs carrying payload miRNAs for targeted anticancer therapyPeng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, et al.
Cancer Research Communications|October 23, 2024
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer CellsZachary A Schaaf, Shu Ning, Amy R Leslie, et al.
Frontiers in Oncology|March 13, 2020
The Optimal Outcome of Suppressing Ewing Sarcoma Growth <i>in vivo</i> With Biocompatible Bioengineered miR-34a-5p ProdrugDai-Feng Li, Ying Yuan, Mei-Juan Tu, et al.
Molecular Cancer Therapeutics|August 5, 2022
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide TreatmentShu Ning, Chengfei Liu, Wei Lou, et al.
Pageof 14